ABSTRACT
INTRODUCTION
Large-scale genome-wide assocation studies (GWAS) have converged on specific risk loci for schizophrenia (SZ) 1 . One of the most robust findings is the TCF4 (transcription factor 4) region on chromosome 18q21.2 2 . First discovered in GWAS meta-analysis 3 , the finding remained significant in a follow-up study 4 and a large family-based replication study 5 . Most pertinently, single nucleotide polymorphisms (SNPs) at TCF4 were among the top findings (p=3.34 x 10 -12 ) in the 2014 Psychiatric Genomics Consortium (PGC) mega-analysis of SZ 1 . Congruent with the association with SZ, TCF4 has also been associated with SZ endophenotypes such as neurocognition and sensorimotor gating [6] [7] [8] .
The biology of TCF4 suggests a plausible role in CNS disorders: 1) TCF4 encodes a transcription factor abundantly expressed in brain that has been implicated in neuronal development 9 and function 10, 11 . 2) Mutations at TCF4 causes Pitt-Hopkins Syndrome (PHS), a rare genetic disorder characterized by neurological deficits including mental retardation 2,12-14 . 3) Balanced chromosomal rearrangements in patients with neurodevelopmental disorders have encompassed TCF4 15 . 4) TCF4 is a target for transcriptional regulation by microRNA 137 (gene ID: MIR137) 16 , which is also a top association finding for SZ 1 . 5) Transgenic mice that overexpress TCF4 have cognitive and sensorimotor impairments 17 , which mirror deficits observed in SZ patients. Overall, the biological rationale linking TCF4 to the CNS and SZ is compelling 2 , suggesting that further study of this gene could advance our understanding of SZ pathogenesis.
The protein encoded by TCF4 is a basic helix-loop-helix (bHLH) transcription factor (TF) that recognizes an Ephrussi-box ('E-box') binding site ('CANNTG') 2, 9, 18 . However, this motif is too small and non-specific to accurately predict TCF4 binding computationally. A precise map of binding sites is vital for deciphering the gene regulatory networks under the influence of a TF 19 . In recent years, systematic mapping of TF binding has been enabled via chromatin immunoprecipitation coupled to next-generation sequencing (ChIP-seq) 20 . ChIP-seq works by precipitating the desired protein-DNA complex out of cell lysate using an antibody complementary to the protein of interest. After removal of the protein, the liberated DNA fragments are sequenced and mapped back to the reference genome to yield a map of regions bound by the protein 21 ( Figure 1a ).
The ENCODE Consortium, which aims to map all regulatory elements in the human genome, has used ChIP-seq extensively to map binding profiles of many TFs in human cell lines 22 . TF binding is tissue-specific, so separate experiments are required to characterize binding in cells from each tissue of interest. At its outset, ENCODE did not have a major CNS focus 23 . The consortium attempted to map TCF4 binding sites in bone marrow-derived K562 cells, (https://www.encodeproject.org/experiments/ENCSR000FCF/). However, these data were revoked shortly after release. To redress the lack of information on TCF4 binding sites, here we describe TCF4
ChIP-seq in a CNS-derived cell line. To probe the relationship with SZ, we tested the TCF4 gene network for overlap with SZ risk genes from GWAS and gene expression studies.
MATERIALS AND METHODS
TCF4 nomenclature Transcription Factor 4, located on chromosome 18, was previously known by the aliases E2-2, ITF-2, PTHS, and SEF-2 (http://www.ncbi.nlm.nih.gov/gene/6925). TCF4 and TCF7L2 (Gene ID: 6934) are often confused because they share the TCF4 alias 9, 25 . TCF7L2, located on chromosome 10, encodes "T-Cell Factor 4", an effector of β-catenin signaling 36 . However, it has not been linked to SZ. In this study, all references to TCF4 are to the gene with co-ordinates chr18:52889562-53332018 (hg19) and these identifiers: HUGO name=TCF4, ENTREZ=6925, HGNC=11634, ENSEMBL=ENSG00000196628, and UNIPROT=P15884.
Antibody selection At the start of this study, no ChIP-grade antibodies were available for TCF4, so we selected candidate antibodies from commercial vendors. Due to the confusion in nomenclature with TCell Factor 4, we discovered several mislabeled antibodies. Therefore, we limited ourselves to antibodies with published epitope sequences that could be confirmed as TCF4 via protein BLAST (NCBI). Eight antibodies were selected, of which three passed initial QC and were used for ChIP-seq: polyclonal anti-TCF4 antibodies K-12 (sc-48947) and N-16 (sc-48949) from Santa Cruz Biotechnology (Dallas, TX) and monoclonal anti-TCF4 antibody 1G4 (Novus, Littleton, CO).
Cell culture SH-SY5Y cells (ATCC, Manassas, VA) were cultured according to supplier's standard protocols.
Antibody validation
We closely followed published ENCODE guidelines for antibody validation 24 . In addition to Western blotting of SH-SY5Y cell lysates, we used immunoprecipitation (IP) of TCF4 protein followed by Western blotting or protein mass spectrometry to characterize the proteins captured in IP (see Supplementary Methods).
Chromatin Immunoprecipitation sequencing (ChIP-seq) Each ChIP assay used approximately 1.2x10 7 SH-SY5Y cells and was performed with the SOLiD ChIP-Seq Kit (Life Technologies) according to manufacturer's specifications, with some adjustments (Supplementary Methods). ChIP-Seq libraries were validated using the BioAnalyzer high-sensitivity chip assay (Agilent) prior to multiplexed high throughput sequencing on the SOLiD 5500 platform. 50 bp single end reads were generated, with a target read number of 25 million tags per sample. In addition to ChIP samples using anti-TCF4 antibodies, their respective IgG controls and input DNA controls were sequenced.
ChIP-seq data analysis Reads were aligned to the human genome (build hg19) using BioScope 1.2 (Life Technologies). Multi-mapping reads were discarded and only stringent single alignments retained.
Sample files were output as .bam files using BioScope. PCR duplicates were removed and alignment files were written in tagAlign.gz format using Samtools 25 and Bedtools 26 . To call peaks and assess experiment quality, we used the SPP peak caller 21 distributed with phantompeakqualtools 27 (https://code.google.com/archive/p/phantompeakqualtools/). A false discovery rate (FDR) threshold of 1%, as implemented in SPP, was used to call peaks. Any peaks that mapped to hg19 ENCODE blacklisted regions (ftp://encodeftp.cse.ucsc.edu/users/akundaje/rawdata/blacklists/hg19/ wgEncodeHg19ConsensusSignalArtifactRegions.bed.gz) were removed. Tissue-specific expression of the top TCF4 genes was tested using the "Gene2Func" mode in FUMA (Functional Mapping and Annotation) 29 .
Data Integration
For cell-specific expression analysis, we obtained single cell RNA-seq data from five brain regions in mice (9970 single cells) that were previously clustered into 24 different cell types 30 .
Normalization factors were computed for each of the 9970 single cells using the scran R package 31, 32 using the 50% of the genes with mean expression higher than the median. The normalization factors were computed after clustering cells using the scran quickcluster() function to account for cell type heterogeneity. We then performed 24 differential expression analyses using BPSC 33 testing each cell type against the 23 other cell types using the normalization factor as a covariate. For each differential expression analysis, the t-statistics were then transformed to a standard normal distribution. Finally, for each cell type, we used linear regression to test if the standard normalized t-statistics for genes in the TCF4 gene set were significantly higher than for genes not in the gene set.
Enrichment testing of TCF4 binding sites in significant genes from siRNA knockdown expression studies 34, 35 was carried out by mapping genes ± 10 kb, followed by one-sided Fisher exact tests. Permutation testing of significant findings used the shiftR package (https://github.com/andreyshabalin/shiftR), as outlined previously 36 . Test of overlap between TCF4 peaks and genomic annotations used the LOLA (Locus Overlap Analysis) Bioconductor package 37 , with all mappings obtained from the LOLACore annotation set (databio.org/regiondb). The background set for this analysis was the default DNase hypersensitive sites (DHS) in multiple tissues ("activeDHS" set), which captures known human regulatory regions 37, 38 . Testing for overlap with Psychiatric Genomics Consortium SZ findings was also based on genomic locus, rather than gene. SZ-associated loci were obtained by download of the "scz2.anneal.108" file from the PGC website (https://www.med.unc.edu/pgc/results-and-downloads). Background sets for this analysis were either "activeDHS" as above or DNase hypersensitive sites specifically for SK-N-SH cells ("wgEncodeOpenChromDnaseSknshPk" track, Duke DHS from ENCODE). No DHS data for SH-SY5Y
were available, but SH-SY5Y are a subline of SK-N-SH isolated from the same donor 39 . After matching to the background sets, enrichment testing used Fisher exact tests followed by permutation as above.
RESULTS

ChIP-seq and peak calling
At the start of the project, no validated ChIP antibodies were available for TCF4. Of eight candidate anti-TCF4 antibodies identified, three passed initial immunoblot testing according to ENCODE guidelines, whereby a single band of the appropriate mass accounting for >50% of the total lane intensity was observed 24 (Figure 1b) . We performed IP cross-reactivity studies using these antibodies, where IP with anti-TCF4 antibodies was used as the substrate for Western blot with a different anti-TCF4 antibody. Figure 1c shows that anti-TCF4 antibodies K-12 and N-16 immunoprecipitated a protein of the appropriate mass that was detected by monoclonal anti-TCF4 antibody 1G4, indicating that all three antibodies were likely detecting the same protein. We also conducted mass spectrometry-based proteomics analysis of the IP of all three antibodies and successfully detected TCF4 peptides in each case (Supplementary Figures S1 and S2), while we did not detect any in IgG control (mock IP) experiments. We therefore proceeded with ChIP-seq using these antibodies.
Each ChIP experiment involved isolating TCF4-bound DNA from approximately 1.2x10 7 SH-SY5Y cells. Average DNA yield was within expected parameters (~10 ng per replicate), but DNA was also recovered from ChIP using the control IgG antibodies. This indicated that non-specific material was captured and that mock IP ChIP-seq was the appropriate background experiment to call peaks.
We conducted each ChIP in triplicate and met/exceeded ENCODE guidelines for a minimum of 10 7 uniquely-aligned reads per ChIP replicate 24 . However, only one replicate each for two of the three antibodies (K-12 and N-16) showed good enrichment. Figure 1d shows the summary statistics for these assays and cross-correlation plots are provided in Supplementary Figures S3 and S4.
After filtering out ENCODE blacklisted regions, the number of peaks called in each of the two successful experiments was 77,167 for antibody K-12 and 70,551 for antibody N-16, using a stringent False Discovery Rate (FDR) threshold of 1% (Figure 1d ). This large number of peaks is typical in ChIPseq experiments, where peaks can number in the tens or hundreds of thousands 40, 24 .
Peak consistency and genomic distribution
We examined overlap between peaks called in our two experiments. First, we plotted the difference in starting position between peaks observed in K-12 ChIP-seq and the closest peak in N-16
ChIP-seq. Figure 2a shows that there was a clear enrichment for peaks with start sites ± 200 bp in each experiment. This is the approximate peak size (~225 bp) in the 'narrowpeak' output format used by the SPP peak caller. Therefore, we specified that the peaks called in the two separate experiments had to overlap (at least 1bp in common) to count as "replicated"; neighboring, non-overlapping peaks were not considered. Applying this criterion resulted in 11,322 TCF4 binding sites present in both experiments.
As expected, overlap was greater for peaks called with higher confidence. Sorting SPP signalValue, 65% of peaks in the top 100 in the K-12 experiment had a matching peak in the N-16 data; 50% in the top 250; 45% in the top 500; and 29% in the top 5000.
TCF4 binds the 'Ebox' sequence motif ('CANNTG'). Overall, 86.4% of the 11,322 binding sites encompassed an Ebox. There was a marginal enrichment among the top findings, whereby 90% of the top 500 sites encompassed an Ebox compared to 85.6% for the bottom 500. However, Ebox motifs are small, redundant and occur frequently in the genome (>14 million in hg19). Therefore they are a nonspecific indicator of ChIP-seq success. Figure 2b shows the distribution of all 11,322 binding sites by chromosome. No binding sites were obtained for the chrY because SH-SY5Y is genetically female. If the binding sites were random, most would occur on Chr1, the largest chromosome, with decreasing numbers to Chr21, the smallest.
However, we observe a distinctly nonrandom distribution with relatively large numbers of peaks detected on chrs 7 and 17. The full set of 11,322 binding sites are provided in Supplementary Table S1 .
Genes associated with TCF4 binding sites and their tissue-specific expression
To obtain insight into TCF4's functional role, we used GREAT 28 to conduct enrichment tests for GO categories and MSigDB pathways. GREAT first assigns genomic loci to regulatory domains associated with genes. Only 34 TCF4 binding sites could not be assigned to any genes (Supplementary Figure S5) . The results from GREAT are shown in Table 1 . Significant results in the GO cellular component category had a strong neuronal theme, while insulin signaling and axon/neuronal development were notable pathway findings.
The full set of 11,322 TCF4 binding sites implicated 6528 unique genes ±10 kb of the gene body (Supplementary Table S2 ), which is approximately one quarter of all genes in refGene, including noncoding RNAs and genes with provisional nomenclature designations. We used FUMA 29 to test for enrichment in tissue-specific differentially expressed gene sets (Supplementary Figure S6) . The TCF4 gene set was most enriched in genes up-regulated in the brain and pituitary, and genes down-regulated in the heart and blood vessels. To further probe the expression patterns of the TCF4 gene set, we looked at single cell RNA-seq data for specific CNS cell types. We observed that the TCF4 gene set was significantly over-expressed in pyramidal neurons from the somatosensory cortex (P = 5.2x10 -5 , Figure 3 ).
Differential regulation of TCF4 genes in siRNA knockdown experiments and post-mortem data
We integrated our ChIP-seq data with relevant datasets to refine our findings and identify SZ risk genes under TCF4 control. We first tested for overlap between the TCF4 gene set and gene expression data from a TCF4 knockdown experiment using small interfering RNA (siRNA), also conducted in SH-SY5Y cells 34 . We expected that genes differentially expressed following TCF4 knockdown should be enriched for those with TCF4 binding sites from ChIP-seq. A significant enrichment was observed and this was driven by genes downregulated following TCF4 knockdown (Table 2) . No significant enrichment was observed in the upregulated genes. We also tested the TCF4 gene set for enrichment in a second TCF4 siRNA knockdown experiment, this time in cortical neuron progenitor cells 35 (Table 2) . Once again downregulated genes, but not upregulated genes, were significantly enriched. This consistency was encouraging. All genes overlapping between ChIP-seq and siRNA studies are provided in Supplementary Tables S4 and S5. We next tested if the TCF4 gene set was enriched among genes differentially expressed in post-mortem brain tissue from SZ patients. Here we used findings from Fromer et al. (2016) 41 , who conducted bulk RNA-seq of dorsolateral prefrontal cortex (DLPFC) from 258 SZ cases and 279 controls. Once again, downregulated genes were significantly enriched with almost half possessing a TCF4 binding site, compared to just 12.5% of the up-regulated genes. This highly significant enrichment in down-regulated genes was surprising because these are downregulated in SZ, not as a direct result of TCF4 knockdown. We hypothesized that TCF4 is driving the down-regulation of genes in SZ by being downregulated itself, analogous to the situation in the siRNA experiments. However, TCF4 expression was significantly upregulated in the SZ patients (fold enrichment = 1.16, Fromer et. al, their
Supplementary Data File 3 41 ). Further analysis of these gene sets showed that few genes were shared in common. That is, only seven genes with TCF4 binding sites from ChIP-seq were down-regulated in the SH-SY5Y siRNA study 34 and down-regulated in the SZ expression study 41 . These were ANKMY1, FAM78A, IGF2, MXRA8, NT5M, PELI3 and TNS3. Notably, IGF2 had the largest fold-change reduction of all genes in the Fromer et al. study. A further two genes with TCF4 binding sites, DBNL and PNPLA7, showed downregulation in the neural progenitor cell siRNA study 35 and the SZ gene expression study.
Overlap of TCF4 binding sites with other TFs and SZ risk loci
We next considered overlap of TCF4 binding sites with UCSC genome browser features. TCF4 binding sites were highly enriched (OR=7.08) in CpG islands, classified according to the Weizmann Institute CpG evolution model 42 , and in transcription start sites (OR=3.19) from the SwitchGear Genomics library (www.switchgeargenomics.com) ( Table 2 ). These are consistent with the binding profile of a TF. We also looked at overlap with binding profiles for other TFs from ENCODE. Notable overlapping factors were FOXP2, a neural transcription factor involved in speech development 43 , and p300, a chromatin remodeler encoded by the EP300 gene that is associated with SZ 1 . this analysis, we used genomic locus-based enrichment rather than gene sets. This is important because many SZ-associated genes are large and may be more likely to overlap genomic annotations by chance than a randomly selected gene set 44 . Therefore, annotations can be confounded with gene size, leading to erroneous conclusions of enrichment. Testing for TCF4 binding site enrichment in the associated genomic regions, and not considering occurrence in genes, obviates this potential bias.
Overall, 39 of the 108 PGC SZ loci contained one or more TCF4 binding sites, with 130 sites in total falling within their boundaries. Permutation testing of enrichment using all known human regulatory regions as the background set revealed a non-significant overlap (p=0.082). Narrowing the background set to relevant regulatory regions for the cell type used in the ChIP-seq experiments revealed a nominally significant enrichment (p=0.035) ( Table 1) . PGC SZ genes with TCF4 binding sites ±10 kb that were also differentially expressed in either of the siRNA experiments described above were
APH1A, C1orf54, CENPM, CHRNA5, DFNA5, GFOD2, GRAMD1B, LRP1, MPP6, PDCD11, SEZ6L2,
TLE1, and XRCC3. Of these, both LRP1 and XRCC3 had three binding sites in our ChIP-seq data, PDCD11 had two, while the remainder had one each.
DISCUSSION
We obtained data on TCF4 binding from two separate ChIP-seq experiments, which allowed us to probe the TCF4 gene network for association with SZ risk genes. In our ChIP-seq experiments, only two out of three antibodies yielded usable data. The ENCODE Consortium attempted TCF4 ChIP-seq in K562 cells but revoked their data because of poor quality. Therefore, consistently obtaining high quality TCF4 ChIP-seq data may be a challenge. The simplest explanation may be that none of the antibodies so far used in TCF4 ChIP-seq are particularly well suited to this purpose. It is accepted that antibodies that pass initial characterization may still fail to yield good ChIP-seq data 24 . Yet between the ENCODE experiments and ours, at least four antibodies have been used in TCF4 ChIP-seq, with only two yielding acceptable data. We speculate that the complex nature of TCF4 itself may contribute to this variability. The TCF4 locus can give rise to 18 potentially distinct isoforms via alternative splicing 18 .
Some isoforms are exclusively nuclear while others rely on heterodimerization partners. Furthermore, different isoforms may contain one or two transcription activation domains that act synergistically in combination 18 . It is therefore plausible that relative expression of different isoforms varies significantly over time, in conjunction with the expression of functional partner proteins. Further work will be needed to understand the impact of this complexity for SZ.
Our data was generated in the SH-SY5Y cell line, which is commonly used in CNS research.
However, it is a transformed line that will have differences in gene expression from healthy neurons in vivo and it is well-known that TF binding is highly cell-specific 22, 45 . Unfortunately, transformed cells are a practical necessity. The very low DNA yields in ChIP-seq mean that millions of cells are needed for each experiment. These numbers are extremely difficult to obtain for primary cells, particularly human neurons. Methods that yield high quality data from very low DNA input quantities are urgently needed in this area. Nevertheless, our data did indicate that genes implicated by our TCF4 binding sites were enriched in brain expressed gene sets. Furthermore, using single cell RNA-seq data, we observed enrichment of the TCF4 gene set among genes expressed in pyramidal neurons of the somatosensory cortex, a cell type that was previously associated with schizophrenia 30 .
Several genes that we identified as having TCF4 binding sites have been functionally linked with TCF4 in prior studies. For example, TCF4 has also been shown to affect neural excitability via repression of potassium channel KCNQ1 11 . In our data, this gene had 19 unique TCF4 binding sites, the 16 th largest number for any gene. Conversely, given the problems with "TCF4" nomenclature, delineating what is not seen in our data may be of value. Several articles describe the interaction between "TCF4", β-catenin and p300 46 . This relates to T Cell Factor 4, encoded by TCF7L2. Betacatenin is encoded by CTNNB1 and we did not detect a TCF4 binding site at this gene. Furthermore, even though the binding profiles of p300 (encoded by EP300) and TCF4 strongly overlap (Table 2) , TCF4 does not appear to regulate EP300, at least in our data. The co-occurrence of their binding sites does, however, imply that they may be involved in the regulation of a partially overlapping set of genes in CNS cells. EP300 is a PGC2 SZ risk locus 1 and was associated with emotional processing in functional neuroimaging experiments 47 . Further analysis into the overlapping pathways regulated by these two SZ-associated DNA binding proteins may be relevant.
Several genes with TCF4 binding sites in our ChIP-seq data were significantly enriched among those down-regulated in TCF4 siRNA knockdown experiments. However, the ORs of enrichment were fairly modest, even for siRNA knockdown that used the same cell line (SH-SY5Y) as our ChIP-seq experiments. This can be explained because not all genes differentially expressed in a TCF4 siRNA knockdown experiment will be directly under TCF4 control 35 . Those genes that TCF4 directly affects can, in turn, affect the expression of others. Similarly, ChIP-seq data can be noisy and the number of peaks can exceed the numbers of genes a TF directly regulates, possibly as the result of sporadic binding 40 . By identifying the overlap between ChIP-seq and siRNA data, this allows us to cancel out some of the noise inherent to each strategy. This should provide a better indicator of genes under direct TCF4 control, since it combines direct physical interaction of the TF with a functional effect on expression.
A subset of genes with TCF4 binding sites were differentially expressed in siRNA studies and dysregulated in post-mortem brain tissue from SZ patients. Among these, IGF2 (insulin-like growth factor 2) was the most down-regulated gene in postmortem SZ brain 41 . IGF2 may regulate neural plasticity to modulate behavior and memory 50 . Furthermore, deficits in hippocampal neurogenesis in a mouse model of 22q11.2 deletion-associated SZ can be rescued by IGF2 51 . A significant amount of work has been conducted on the role of IGF2 in the brain, yet few studies address the role of IGF2 in SZ etiology. One issue is that IGF2 was not detected among PGC SZ risk loci 1 . This may indicate that down-regulation of IGF2 in SZ is a consequence of risk variants at other loci or environmental factors, rather than as a result of risk variants at the IGF2 locus itself.
On the other hand, several PGC SZ risk genes did contain TCF4 binding sites, although the enrichment was modest. Thirteen such genes also showed differential expression in TCF4 siRNA experiments. The risk loci identified by the PGC may span several hundred kb and contain many genes. It is often not apparent which genes in these regions should be selected for further study.
PDCD11 is likely regulated by TCF4, exhibiting both TCF4 binding sites and differential expression in a TCF4 siRNA study. It is also expressed in brain 53 and located on chromosome 10, in the third most significant region identified by the PGC (chr10:104423800-105165583, P-value = 6.12E-19) 1 . There are 14 genes in this region and PDCD11 is poorly characterized. However, its likely regulation by TCF4 may suggest further work is merited to characterize this interaction.
With robust risk loci implicated in SZ and the shift of focus to functional experiments and data integration, the onus is now on interpreting overlap between genome-wide profiles and identifying themes in complex datasets involving hundreds of relevant elements. Dissecting these complex interactions to tease out the causal networks relevant for psychiatric phenotypes is of paramount importance. Enrichment of TCF4 gene set expression in specific cell types as determined by single cell RNA-seq 30 .
We tested if expression of genes in the TCF4 gene set were significantly higher than for genes not in the gene set for each cell type. The bold line at ~2.7 on the x-axis is the Bonferroni-adjusted -log 10 (pvalue) for multiple testing (α=0.05/24). 
